These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31577465)

  • 1. Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.
    Amcoff K; Cao Y; Zhulina Y; Lampinen M; Halfvarson J; Carlson M
    Scand J Gastroenterol; 2019 Oct; 54(10):1237-1244. PubMed ID: 31577465
    [No Abstract]   [Full Text] [Related]  

  • 2. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
    Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and shared environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients.
    Halfvarson J; Ling Lundström M; Lampinen M; Schoultz I; Bodin L; Carlson M
    Scand J Gastroenterol; 2020 Oct; 55(10):1163-1170. PubMed ID: 32815414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD.
    Ling Lundström M; Peterson C; Hedin CRH; Bergemalm D; Lampinen M; Magnusson MK; Keita ÅV; Kruse R; Lindqvist CM; Repsilber D; D'Amato M; Hjortswang H; Strid H; ; Söderholm JD; Öhman L; Venge P; Halfvarson J; Carlson M
    Aliment Pharmacol Ther; 2024 Sep; 60(6):765-777. PubMed ID: 38997818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
    Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
    Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease.
    Saitoh O; Kojima K; Sugi K; Matsuse R; Uchida K; Tabata K; Nakagawa K; Kayazawa M; Hirata I; Katsu K
    Am J Gastroenterol; 1999 Dec; 94(12):3513-20. PubMed ID: 10606313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea.
    Wagner M; Sjöberg K; Vigren L; Olesen M; Benoni C; Toth E; Carlson M
    Scand J Gastroenterol; 2016 Jul; 51(7):835-41. PubMed ID: 26854205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
    Gisbert JP; McNicholl AG
    Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
    Burri E; Beglinger C
    Swiss Med Wkly; 2012; 142():w13557. PubMed ID: 22481443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
    Smith LA; Gaya DR
    World J Gastroenterol; 2012 Dec; 18(46):6782-9. PubMed ID: 23239916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
    Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Faecal calprotectin in inflammatory bowel disease].
    Sipponen T; Kolho KL
    Duodecim; 2011; 127(24):2631-7. PubMed ID: 22320105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.